Abstract
Treatment of malignant pleural mesothelioma (MPM) with Ranpirnase (Onconase) results in disruption of protein translation and cell apoptosis. We hypothesize that Onconase exerts an effect via downregulation of nuclear factor kappa B (NFKβ) by specific microRNAs (miRNAs) and that interference of this pathway could have implications for MPM resistance to chemotherapy. Three immortalized MPM cell lines (H2959, H2373 and H2591) were exposed to Onconase at 0–20 μg/ml. Cell counts were measured at 48 and 72 h. Gene expression in miRNA-enriched RNA was validated by reverse transcription–PCR (RT–PCR). The functional implications of miRNA expression were evaluated by transfecting miRNA mimics or inhibitors into MPM cell lines, and performing Matrigel invasion, cell proliferation, soft agar colony formation and scratch closure assays. Effects on NFKβ expression and downstream targets including ABC transporters, BCL-xl and IAP were assessed by RT–PCR and western blotting. Treatment with 20 μg/ml of Onconase significantly decreased cell count and invasion. Hsa-miR-17* was significantly upregulated and hsa-miR-30c was significantly downregulated by Onconase treatment in all cell lines. Forced expression of hsa-miR-17* mimic and hsa-miR-30c inhibitor each significantly decreased functional activity of Onconase in all assays. NFKB1 (p50) expression and downstream targets were also decreased with Onconase treatment, as well as with forced expression of miRNA mimic and inhibitors. Onconase treatment caused a significant decrease in cell proliferation, invasion and in expression of certain miRNAs. Recapitulation of the resultant miRNA expression pattern with hsa-miR-17* mimic and hsa-miR-30c inhibitor resulted in downregulation of NFKB1 and reduced malignant behavior in functional assays. Thus, Onconase likely exerts its antitumor effect through these miRNAs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ambros V . (2004). The functions of animal microRNAs. Nature 431: 350–355.
Ambros V, Lee RC, Lavanway A, Williams PT, Jewell D . (2003). MicroRNAs and other tiny endogenous RNAs in C. elegans. Curr Biol 13: 807–818.
Ardelt B, Ardelt W, Darzynkiewicz Z . (2003). Cytotoxic ribonucleases and RNA interference (RNAi). Cell Cycle 2: 22–24.
Ardelt B, Juan G, Burfeind P, Salomon T, Wu JM, Hsieh TC et al. (2007). Onconase, an anti-tumor ribonuclease suppresses intracellular oxidative stress. Int J Oncol 31: 663–669.
Barnhart BC, Peter ME . (2003). The TNF receptor 1: a split personality complex. Cell 114: 148–150.
Bartel DP . (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281–297.
Beck AK, Pass HI, Carbone M, Yang H . (2008). Ranpirnase as a potential antitumor ribonuclease treatment for mesothelioma and other malignancies. Future Oncol 4: 341–349.
Cao X, Rodarte C, Zhang L, Morgan CD, Littlejohn J, Smythe WR . (2007). Bcl2/bcl-x(L) inhibitor engenders apoptosis and increases chemosensitivity in mesothelioma. Cancer Biol Ther 6: 246–252.
Carbone M, Albelda SM, Broaddus VC, Flores RM, Hillerdal G, Jaurand MC et al. (2007). Eighth international mesothelioma interest group. Oncogene 26: 6959–6967.
Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT et al. (2005). Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33: e179.
Davidson AL, Dassa E, Orelle C, Chen J . (2008). Structure, function, and evolution of bacterial ATP-binding cassette systems. Microbiol Mol Biol Rev 72: 317–364.
Deptala A, Halicka HD, Ardelt B, Ardelt W, Mikulski SM, Shogen K et al. (1998). Potentiation of tumor necrosis factor induced apoptosis by onconase. Int J Oncol 13: 11–16.
Dickson KA, Haigis MC, Raines RT . (2005). Ribonuclease inhibitor: structure and function. Prog Nucleic Acid Res Mol Biol 80: 349–374.
Gillet JP, Efferth T, Remacle J . (2007). Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 1775: 237–262.
Gilmore TD . (1999). The Rel/NF-kappaB signal transduction pathway: introduction. Oncogene 18: 6842–6844.
Gilmore TD . (2003). The Re1/NF-kappa B/I kappa B signal transduction pathway and cancer. Cancer Treat Res 115: 241–265.
Gilmore TD . (2006). Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 25: 6680–6684.
Gordon GJ, Mani M, Mukhopadhyay L, Dong L, Yeap BY, Sugarbaker DJ et al. (2007). Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma. J Pathol 211: 439–446.
Halicka DH, Pozarowski P, Ita M, Ardelt WJ, Mikulski SM, Shogen K et al. (2002). Enhancement of activation-induced apoptosis of lymphocytes by the cytotoxic ribonuclease onconase (Ranpirnase). Int J Oncol 21: 1245–1250.
Iordanov MS, Ryabinina OP, Wong J, Dinh TH, Newton DL, Rybak SM et al. (2000). Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase: evidence for cytotoxic mechanisms different from inhibition of protein synthesis. Cancer Res 60: 1983–1994.
Jones PM, George AM . (2004). The ABC transporter structure and mechanism: perspectives on recent research. Cell Mol Life Sci 61: 682–699.
Kasashima K, Nakamura Y, Kozu T . (2004). Altered expression profiles of microRNAs during TPA-induced differentiation of HL-60 cells. Biochem Biophys Res Commun 322: 403–410.
Kaufman AJ, Pass HI . (2008). Current concepts in malignant pleural mesothelioma. Expert Rev Anticancer Ther 8: 293–303.
Khokhar NZ, She Y, Rusch VW, Sirotnak FM . (2001). Experimental therapeutics with a new 10-deazaaminopterin in human mesothelioma: further improving efficacy through structural design, pharmacologic modulation at the level of MRP ATPases, and combined therapy with platinums. Clin Cancer Res 7: 3199–3205.
Kim DH, Kim EJ, Kalota A, Gewirtz AM, Glickson J, Shogen K et al. (2007). Possible mechanisms of improved radiation response by cytotoxic RNase, Onconase, on A549 human lung cancer xenografts of nude mice. Adv Exp Med Biol 599: 53–59.
Kobe B, Deisenhofer J . (1996). Mechanism of ribonuclease inhibition by ribonuclease inhibitor protein based on the crystal structure of its complex with ribonuclease. A J Mol Biol 264: 1028–1043.
Lagos-Quintana M, Rauhut R, Meyer J, Borkhardt A, Tuschl T . (2003). New microRNAs from mouse and human. RNA 9: 175–179.
Lee I . (2008). Ranpirnase (Onconase), a cytotoxic amphibian ribonuclease, manipulates tumour physiological parameters as a selective killer and a potential enhancer for chemotherapy and radiation in cancer therapy. Expert Opin Biol Ther 8: 813–827.
Lee I, Kim DH, Sunar U, Magnitsky S, Shogen K . (2007). The therapeutic mechanisms of ranpirnase-induced enhancement of radiation response on A549 human lung cancer. In vivo 21s: 721–728.
Lee JE, Raines RT . (2008). Ribonucleases as novel chemotherapeutics: the ranpirnase example. BioDrugs 22: 53–58.
Littlejohn JE, Cao X, Miller SD, Ozvaran MK, Jupiter D, Zhang L et al. (2008). Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts. Int J Cancer 123: 202–208.
Micheau O, Tschopp J . (2003). Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114: 181–190.
Mikulski SM, Viera A, Darzynkiewicz Z, Shogen K . (1992). Synergism between a novel amphibian oocyte ribonuclease and lovastatin in inducing cytostatic and cytotoxic effects in human lung and pancreatic carcinoma cell lines. Br J Cancer 66: 304–310.
O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT . (2005). c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435: 839–843.
Pass HI, Liu Z, Wali A, Bueno R, Land S, Lott D et al. (2004). Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res 10: 849–859.
Pass HI, Stevens EJ, Oie H, Tsokos MG, Abati AD, Fetsch PA et al. (1995). Characteristics of nine newly derived mesothelioma cell lines. Ann Thorac Surg 59: 835–844.
Pavlakis N, Vogelzang NJ . (2006). Ranpirnase--an antitumour ribonuclease: its potential role in malignant mesothelioma. Expert Opin Biol Ther 6: 391–399.
Porta C, Paglino C, Mutti L . (2008). Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma. Biologics 2: 601–609.
Reck M, Krzakowski M, Jastrzebski D et al. (2009). Randomized, multicenter phase III study of ranpirnase plus doxorubicin (DOX) versus DOX in patients with unresectable malignant mesothelioma (MM). J Clin Oncol 27(Suppl.):abstr 7507.
Robinson BW, Lake RA . (2005). Advances in malignant mesothelioma. N Engl J Med 353: 1591–1603.
Robledo R, Mossman B . (1999). Cellular and molecular mechanisms of asbestos-induced fibrosis. J Cell Physiol 180: 158–166.
Rybak SM, Pearson JW, Fogler WE, Volker K, Spence SE, Newton DL et al. (1996). Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease. J Natl Cancer Inst 88: 747–753.
Saxena SK, Sirdeshmukh R, Ardelt W, Mikulski SM, Shogen K, Youle RJ . (2002). Entry into cells and selective degradation of tRNAs by a cytotoxic member of the RNase A family. J Biol Chem 277: 15142–15146.
Shi Z, Parmar S, Peng XX, Shen T, Robey RW, Bates SE et al. (2009). The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance. Oncol Rep 21: 483–489.
Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW et al. (2007). Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 67: 11012–11020.
Shukla S, Robey RW, Bates SE, Ambudkar SV . (2009). Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos 37: 359–365.
Singh UP, Ardelt W, Saxena SK, Holloway DE, Vidunas E, Lee HS et al. (2007). Enzymatic and structural characterisation of amphinase, a novel cytotoxic ribonuclease from Rana pipiens oocytes. J Mol Biol 371: 93–111.
Soini Y, Jarvinen K, Kaarteenaho-Wiik R, Kinnula V . (2001). The expression of P-glycoprotein and multidrug resistance proteins 1 and 2 (MRP1 and MRP2) in human malignant mesothelioma. Ann Oncol 12: 1239–1245.
Soini Y, Kinnula V, Kaarteenaho-Wiik R, Kurttila E, Linnainmaa K, Paakko P . (1999). Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma. Clin Cancer Res 5: 3508–3515.
Symanowski J, Vogelzang N, Zawel L, Atadja P, Pass H, Sharma S . (2009). A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL. J Thorac Oncol 4: 149–160.
Tsai SY, Ardelt B, Hsieh TC, Darzynkiewicz Z, Shogen K, Wu JM . (2004). Treatment of Jurkat acute T-lymphocytic leukemia cells by onconase (Ranpirnase) is accompanied by an altered nucleocytoplasmic distribution and reduced expression of transcription factor NF-kappaB. Int J Oncol 25: 1745–1752.
Varkonyi-Gasic E, Wu R, Wood M, Walton EF, Hellens RP . (2007). Protocol: a highly sensitive RT-PCR method for detection and quantification of microRNAs. Plant Methods 3: 12.
Wang XJ, Reyes JL, Chua NH, Gaasterland T . (2004). Prediction and identification of Arabidopsis thaliana microRNAs and their mRNA targets. Genome Biol 5: R65.
Wu Y, Mikulski SM, Ardelt W, Rybak SM, Youle RJ . (1993). A cytotoxic ribonuclease. Study of the mechanism of onconase cytotoxicity. J Biol Chem 268: 10686–10693.
Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z et al. (2006). TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci USA 103: 10397–10402.
Yang H, Testa JR, Carbone M . (2008). Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol 9: 147–157.
Zhao H, Ardelt B, Ardelt W, Shogen K, Darzynkiewicz Z . (2008). The cytotoxic ribonuclease onconase targets RNA interference (siRNA). Cell Cycle 7: 3258–3261.
Acknowledgements
Ranpirnase was provided by AlphaCell Corporation, Paramus, NJ, USA. We also wish to acknowledge the generous support of Belluck and Fox, LPA for this project. Supported by NCI/NIH EDRN Biomarker Discovery Laboratory Grant UO1CA1111295 to Dr Pass and1PO1 CA114047-D1A1 to Dr Carbone.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Rights and permissions
About this article
Cite this article
Goparaju, C., Blasberg, J., Volinia, S. et al. Onconase mediated NFKβ downregulation in malignant pleural mesothelioma. Oncogene 30, 2767–2777 (2011). https://doi.org/10.1038/onc.2010.643
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2010.643
Keywords
This article is cited by
-
Preventive and therapeutic opportunities: targeting BAP1 and/or HMGB1 pathways to diminish the burden of mesothelioma
Journal of Translational Medicine (2023)
-
Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds
British Journal of Cancer (2020)
-
Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma
Scientific Reports (2014)
-
Molecular functions and significance of the MTA family in hormone-independent cancer
Cancer and Metastasis Reviews (2014)
-
Sialyl-glycoconjugates in cholesterol-rich microdomains of P388 cells are the triggers for apoptosis induced by Rana catesbeiana oocyte ribonuclease
Glycoconjugate Journal (2014)